person
as of 2026-07-01Stefan Leucht, Professor
Stefan LeuchtStefan Leucht, MD
ORCID 0000-0002-4934-4352
at a glance
Roles: Principal Investigator, Author, Investigator+Author
KOL signal score 87
34 publications · 21 high-value
Cross-drug reach: 6 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Klinikum rechts der Isar
Roles
Principal Investigator, Author, Investigator+Author
KOL signal
87
Publications
34 (21 high-value)
Trial investigator
yes
Publishes on
6 drugs
Trials led
2
Publications & congress
24
Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases.
Lancet (London, England) · 2026 · high-value
Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis: A Randomized Clinical Trial.
JAMA psychiatry · 2026 · high-value
Multimodal microglial and kynurenine pathway alterations across the affective-psychosis spectrum: a systematic review of patterns, heterogeneity, and dimensional implications.
Molecular psychiatry · 2026 · high-value
Treatment of bipolar depression: results from a comprehensive network meta-analysis and updated systematic review.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2026 · high-value
Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials.
Molecular psychiatry · 2026 · high-value
Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2025 · high-value
Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis.
CNS drugs · 2025 · high-value
Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study.
Schizophrenia research · 2024 · high-value
Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data.
Wellcome open research · 2024 · high-value
Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
Schizophrenia research · 2024 · high-value
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
The lancet. Psychiatry · 2023 · high-value
Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain.
Psychopharmacology · 2023 · high-value
Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial.
The Journal of clinical psychiatry · 2023 · high-value
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.
Schizophrenia bulletin · 2022 · high-value
Next-step treatment for schizophrenia non-responsive to antipsychotics: a systematic review and network meta-analysis.
EClinicalMedicine · 2026
Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement.
Neuroscience applied · 2026
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on